42C.SI - iX Biopharma Ltd.

SES - SES Delayed Price. Currency in SGD
Show:
Income statement
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
30/06/2019
30/06/2018
30/06/2017
30/06/2016
Total revenue
757
671
6,533
6,381
5,797
Cost of revenue
1,537
1,200
5,156
4,448
4,090
Gross profit
-780
-529
1,377
1,933
1,707
Operating expenses
Research development
2,649
3,765
8,031
4,811
5,610
Selling general and administrative
8,273
7,845
8,673
7,593
6,765
Total operating expenses
10,906
11,594
16,687
10,467
8,430
Operating income or loss
-11,686
-12,123
-15,310
-8,534
-6,723
Interest expense
230
232
267
242
32
Total other income/expenses net
-
-
-
-
-
Income before tax
-12,093
-13,268
-15,155
-7,581
-7,783
Income tax expense
-5
-22
-61
-191
-80
Income from continuing operations
-12,088
-13,246
-15,094
-7,390
-7,703
Net income
-1,913
-2,991
-15,094
-7,390
-7,703
Net income available to common shareholders
-1,913
-2,991
-15,094
-7,390
-7,703
Reported EPS
Basic
-
-0.00
-0.02
-0.01
-0.01
Diluted
-
-0.00
-0.02
-0.01
-0.01
Weighted average shares outstanding
Basic
-
643,830
641,549
638,406
595,408
Diluted
-
647,930
641,549
638,406
595,408
EBITDA
-
-11,820
-13,481
-6,058
-6,819